Answers are grounded in this paper and cite their sources.
Polypharmacy is commonly encountered in human immunodeficiency virus (HIV)-positive patients, and the risk and frequency of drug-drug interactions are significant in this patient population. Most HIV-positive patients receive the antiretroviral drug zidovudine (3'-azido-3'-deoxythymidine, ZDV), the first drug to be approved for the treatment of HIV. Many drug interactions with ZDV have already been reported. As HIV pharmacotherapy becomes more complex, the potential for drug-drug interactions is likely to increase significantly.
No takes yet. Share an insight, caveat, or question.
Robertson‐Dallas et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: